Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2019-2023 | 17% CAGR Projection over the Next Four Years | Technavio

LONDON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/PARPinhibitors?src=hash” target=”_blank”gt;#PARPinhibitorslt;/agt;–The research report on the global PARP (poly ADP-ribose polymerase)
inhibitors market by Technavio
predicts the market to post a CAGR of more than 17% during the
period 2019-2023.

Although there are currently three PARP inhibitors that are approved for
at least three indications, these drugs are being studied in clinical
trial phases for the treatment of various other oncology-related
indications. The application landscape of the PARP inhibitors remains
vast with the clinical stages for these drugs being studied for a
minimum of ten indications. The primary reason for the increase in the
application of these therapies is their high efficacy for the treatment
of solid tumors. The study of a single molecule for multiple indications
helps vendors curtail the costs associated with conducting multiple
pre-clinical and clinical trial studies. This is expected to attract
several vendors to research the application of PARP inhibitors for new
cancer indications. As a result, the global PARP inhibitors market is
expected to witness significant growth during the forecast period.

As per Technavio, the growing prevalence of cancer and the extensive
ongoing research will have a positive impact on the market and
contribute to its growth significantly over the forecast period. This global
PARP (poly ADP-ribose polymerase) inhibitors market 2019-2023
research report also analyzes other important trends and market drivers
that will affect market growth over 2019-2023.

Global PARP (poly ADP-ribose polymerase)
inhibitors market: Growing prevalence of cancer

In recent years, the incidence of cancer has been increasing
significantly owing to changes in lifestyles and a large global
geriatric population. This has led to the development and approval of
various novel therapies in the global oncology therapeutics market.
According to the CDC, cancer is the most common cause of death in the US
and accounts for approximately 25 % of all deaths in the country.
Consequently, vendors have immense opportunities for conducting
substantial research on drugs such as PARP inhibitors for the treatment
of cancer. The need to address the vast unmet needs will add significant
value to the global PARP inhibitors market in the coming years.

“PARP inhibitors are expensive due to high R&D costs. Therefore,
various governments have come up with patient assistance programs to
reduce the cost burden associated with the drugs and offer them at an
affordable price. The increasing number of patient assistance programs
will help provide treatment to more patients, resulting in the value and
volume growth of the PARP inhibitors market,” says a senior research
analyst at Technavio.

Global PARP (poly ADP-ribose polymerase)
inhibitors market: Segmentation analysis

This research report on the PARP inhibitors market segments the market
by indication (ovarian cancer, breast cancer, and others) and geography
(Asia, Europe, North America, and ROW).

The ovarian cancer segment held the largest PARP inhibitors market share
in 2018. However, breast cancer segment is expected to register the
highest incremental growth in the PARP inhibitors market during the
forecast period.

North America accounted for the highest share of the market in 2018 due
to the sale of approved therapeutics and the increasing prevalence of
various solid tumors in the region. The strong pipeline for PARP
inhibitors is another critical factor driving the growth of the market
in this region.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

• Market ecosystem
• Market characteristics
• Market segmentation analysis

Market Sizing

• Market definition
• Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

• Regional comparison
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at [email protected].

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com